William S. York, Alan G. Darvill, Michael McNeil et al.|Methods in enzymology on CD-ROM/Methods in enzymology|1986
Cited by 1.1k
Commonwealth Scientific and Industrial Research Organisation
Publishes on Carbohydrate Chemistry and Synthesis, Mycobacterium research and diagnosis, Glycosylation and Glycoproteins Research. 259 papers and 21.5k citations.
Add your photo, update your bio, and get notified when your ranking changes.
The Hippo pathway was initially discovered in Drosophila melanogaster as a key regulator of tissue growth. It is an evolutionarily conserved signaling cascade regulating numerous biological processes, including cell growth and fate decision, organ size ...Read More
The differential transcriptional response of Mycobacterium tuberculosis to drugs and growth-inhibitory conditions was monitored to generate a data set of 430 microarray profiles. Unbiased grouping of these profiles independently clustered agents of known mechanism of action accurately and was successful at predicting the mechanism of action of several unknown agents. These predictions were validated biochemically for two agents of previously uncategorized mechanism, pyridoacridones and phenothiazines. Analysis of this data set further revealed 150 underlying clusters of coordinately regulated genes offering the first glimpse at the full metabolic potential of this organism. A signature subset of these gene clusters was sufficient to classify all known agents as to mechanism of action. Transcriptional profiling of both crude and purified natural products can provide critical information on both mechanism and detoxification prior to purification that can be used to guide the drug discovery process. Thus, the transcriptional profile generated by a crude marine natural product recapitulated the mechanistic prediction from the pure active component. The underlying gene clusters further provide fundamental insights into the metabolic response of bacteria to drug-induced stress and provide a rational basis for the selection of critical metabolic targets for screening for new agents with improved activity against this important human pathogen.
A revised system of abbreviated names is proposed for xyloglucan‐derived oligosaccharides. Each (1→4)‐linked β‐ d ‐glucosyl residue (and the reducing terminal d ‐glucose moiety) of the backbone is given a one‐letter code according to its substituents. The name of the oligosaccharide consists of these code letters listed in sequence from non‐reducing to reducing terminus of the backbone.